clinical trial · NCT06998771
JSKN003 Combined Treatment of HER2-positive Gastric Cancer
Shanghai JMT-Bio Inc.·phase2·not yet recruiting·n = 153
HER2-positive Gastric CancerJSKN003KN026CapecitabineEnlonstobartOxaliplatinTrastuzumabPembolizumab
brief summary
This study is designed to evaluate the safety and efficacy of JSKN003 combination therapy as first-line treatment in HER2-positive unresectable locally advanced or metastatic gastric cancer or resectable gastric cancer.
started
Jun 15, 2025
primary completion
Jun 30, 2028
completion
Dec 31, 2029
last updated
May 31, 2025
official title
A Phase II Trial to Evaluate the Safety and Efficacy of JSKN003 Combination Therapy as First-line Treatment in HER2-positive Unresectable Locally Advanced or Metastatic Gastric Cancer or Resectable Gastric Cancer
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol